Pathogenesis of lung cancer signalling pathways: roadmap for therapies.
about
Association of Nuclear PIM1 Expression with Lymph Node Metastasis and Poor Prognosis in Patients with Lung Adenocarcinoma and Squamous Cell CarcinomaModulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesFAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway.Visual data mining of biological networks: one size does not fit all.Varied pathways of stage IA lung adenocarcinomas discovered by integrated gene expression analysisAerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer.Defining molecular and cellular responses after low and high linear energy transfer radiations to develop biomarkers of carcinogenic risk or therapeutic outcome.Hepatic arterial therapy with drug-eluting beads in the management of metastatic bronchogenic carcinoma to the liver: a multi-institutional registry.Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based AnalysisGenetic and biochemical alterations in non-small cell lung cancer.Preneoplasia of lung cancerCDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancerExpression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.miR-223/FBW7 axis regulates doxorubicin sensitivity through epithelial mesenchymal transition in non-small cell lung cancer.Roles of the Hippo pathway in lung development and tumorigenesis.TAZ induces lung cancer stem cell properties and tumorigenesis by up-regulating ALDH1A1Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.Screening protein isoforms predictive for cancer using immunoaffinity capture and fast LC-MS in PRM mode.Highly Sensitive and Reliable Detection of EGFR Exon 19 Deletions by Droplet Digital Polymerase Chain Reaction.Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study.Isodeoxyelephantopin induces protective autophagy in lung cancer cells via Nrf2-p62-keap1 feedback loop.A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samplesThe OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategiesGenetic polymorphisms and haplotypes of TRAIL gene correlate with NSCLC susceptibility in a group of Chinese patients.Chalepin: A Compound from Ruta angustifolia L. Pers Exhibits Cell Cycle Arrest at S phase, Suppresses Nuclear Factor-Kappa B (NF-κB) Pathway, Signal Transducer and Activation of Transcription 3 (STAT3) Phosphorylation and Extrinsic Apoptotic PathwayRetinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.Small-cell lung cancer: what we know, what we need to know and the path forward.Molecular challenges of neuroendocrine tumors.MicroRNA, epigenetic machinery and lung cancer.Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation
P2860
Q27853352-3CFA0A7E-25F1-4DF6-86C9-41C4B0E98CA9Q30570945-E3390225-8DBC-4FF4-9A27-19EF36138707Q34419405-6894FF71-BF8B-4AF5-827C-E7D3832D4AFBQ34557957-C44DDF47-6715-4735-9658-137E28620A47Q34941004-CE36A34C-6AD3-4B3B-99F2-2D2CB767D4B3Q35097949-261CD96E-F478-473E-AE64-CDC759F4B894Q35131992-709B20BE-E222-4920-87BA-1719B7158424Q35821428-64E85399-1BF0-4A5F-B895-E130BB1416CBQ35864613-356DBBC6-C2B4-47CF-B0A0-B3646FC2E4C7Q36040002-FD49A3B0-136F-4E17-A179-E05F7AA5290FQ36184584-CC67FCFA-1819-4C88-ACFB-3CA3231E84B2Q36190383-D9EAA4E9-0565-4B64-83E0-FF8B56A64405Q36312135-6065506E-ADAC-40FA-9AD1-2978783D1D0BQ36920386-488B84CE-EA39-48B6-8482-1F2F377D498EQ37060753-BE54115B-E90D-41A5-8FAF-2B66C0E72E00Q38341378-332A0AA8-EB7C-4EB4-A21C-AD5A3F7C957FQ38729543-814C3D83-4C7B-4C09-BF61-F5926B070870Q38753586-69C6551D-032F-4901-8E7E-220B0E7ED941Q38912538-6179EDDA-20B6-4B4F-A248-2F3FF7827FBAQ40476723-034B863E-B945-480B-95C0-42DC250B5D59Q40929491-A592C1B9-9C41-43CE-B0C8-9C7336B3DF62Q41614985-F46055A7-575D-475C-8685-0BA60AB8F847Q41703846-8AF1839E-C125-4043-A972-3D86EA49F040Q42320718-1795169F-7503-4548-B4BB-20F75DF8BB89Q43159916-4455BD79-0A25-461C-B39D-2054FBE13D39Q44017161-53CF4723-5C63-43DB-AB6A-94415B37E3E0Q44568047-06FB7DD5-CBD5-4CC0-93FB-C75722E3BABCQ47595394-ACFA48D3-8655-4E13-BA19-C26632350B97Q49875027-5D6E9E6F-BCFB-43F8-BD4D-BE7E30059D1AQ51711929-B454357B-8364-4B5D-B6D9-3DEA8443BBC7Q58567008-370AEAB5-C126-476F-B074-706C2777421C
P2860
Pathogenesis of lung cancer signalling pathways: roadmap for therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pathogenesis of lung cancer signalling pathways: roadmap for therapies.
@en
Pathogenesis of lung cancer signalling pathways: roadmap for therapies.
@nl
type
label
Pathogenesis of lung cancer signalling pathways: roadmap for therapies.
@en
Pathogenesis of lung cancer signalling pathways: roadmap for therapies.
@nl
prefLabel
Pathogenesis of lung cancer signalling pathways: roadmap for therapies.
@en
Pathogenesis of lung cancer signalling pathways: roadmap for therapies.
@nl
P2860
P1476
Pathogenesis of lung cancer signalling pathways: roadmap for therapies.
@en
P2093
P2860
P304
P356
10.1183/09031936.00014009
P577
2009-06-01T00:00:00Z